Patrick J. Mcenany - Nov 19, 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director, Chairman of Board of Directors
Signature
/s/ Patrick J. McEnany
Stock symbol
CPRX
Transactions as of
Nov 19, 2024
Transactions value $
-$3,022,468
Form type
4
Date filed
11/21/2024, 05:11 PM
Previous filing
Nov 15, 2024
Next filing
Nov 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $348K +98.3K +2.2% $3.54 4.58M Nov 19, 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$2.08M -98.3K -2.15% $21.19 4.48M Nov 19, 2024 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $257K +72.5K +1.62% $3.54 4.55M Nov 20, 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$1.54M -72.5K -1.59% $21.29 4.48M Nov 20, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -98.3K -5.01% $0.00 1.87M Nov 19, 2024 Common Stock 98.3K $3.54 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -72.5K -3.89% $0.00 1.79M Nov 20, 2024 Common Stock 72.5K $3.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.11 to $21.31 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.05 to $21.455 per share.
F4 Options vested in three equal tranches on May 29, 2019, 2020 and 2021.